Search Results

You are looking at 11 - 20 of 251 items for :

  • "Acute Myeloid Leukemia" x
  • Refine by Access: All x
Clear All
Full access

Addressing Knowledge Gaps in Acute Myeloid Leukemia to Improve Referral for Hematopoietic Cell Transplantation Consultation

Christa Meyer, Lih-Wen Mau, Elizabeth A. Murphy, Ellen M. Denzen, Ellyce Hayes, Darlene Haven, Heather Moore, Jackie Foster, Jaime M. Preussler, and Linda J. Burns

Background Hematopoietic cell transplantation (HCT) is an underused therapy for patients with acute myeloid leukemia (AML). 1 Because HCT is performed only at select hospitals in the United States, it is critical to understand physician referral

Full access

Relationship Between Longitudinal Coping Strategies and Outcomes in Patients With Acute Myeloid Leukemia

Hermioni L. Amonoo, Elizabeth Daskalakis, Emma C. Deary, Monica H. Bodd, Matthew J. Reynolds, Ashley M. Nelson, Richard Newcomb, Tejaswini M. Dhawale, Daniel Yang, Selina M. Luger, Jillian L. Gustin, Andrew Brunner, Amir T. Fathi, Thomas W. LeBlanc, and Areej El-Jawahri

Background Coping with a sudden-onset life-threatening illness, intensive chemotherapy, and numerous physical adverse effects can be challenging for many patients with acute myeloid leukemia (AML). 1 , 2 The demands of treatment and recovery

Full access

Identifying Older Patients With Acute Myeloid Leukemia Who May Be Candidates for Reduced-Intensity Hematopoietic Cell Transplantation

Boglarka Gyurkocza and Frederick R. Appelbaum

adults with AML Analyze variables associated with worse prognosis of reduced-intensity HCT among older adults with AML Distinguish advantages of reduced-intensity HCT among older adults with AML T he prevalence of acute myeloid leukemia (AML) increases

Full access

Optimizing Therapy for Acute Myeloid Leukemia

Holbrook E. Kohrt and Steven E. Coutre

Dick JE . Acute myeloid leukemia . Hematology Am Soc Hematol Educ Program 2001 : 62 – 86 . 4. Appelbaum FR Gundacker H Head DR . Age and acute myeloid leukemia . Blood 2006 ; 107 : 3481 – 3485 . 5. Leith CP Kopecky KJ

Full access

Treatment Updates in Acute Myeloid Leukemia

Presented by: Alexander E. Perl

“In the past few years, the NCCN Clinical Practice Guidelines in Oncology [NCCN Guidelines] for Acute Myeloid Leukemia [AML] have had some changes due to new drug approvals. This year, the updates are more incremental than revolutionary, but there

Full access

Non-Transplant Therapy for Older Adults with Acute Myeloid Leukemia

Mikkael A. Sekeres

References 1. Estey EH . How I treat older patients with AML . Blood 2000 ; 96 : 1670 – 1673 . 2. Mayer RJ Davis RB Schiffer CA . Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and

Full access

Strategy for Incorporating Molecular and Cytogenetic Markers into Acute Myeloid Leukemia Therapy

Mark G. Frattini and Peter G. Maslak

Edited by Kerrin G. Robinson

classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial . Blood 2001 ; 98 : 1312 – 1320 . 9. Chang C Storer B Scott B . Hematopoietic cell

Full access

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021

Featured Updates to the NCCN Guidelines

Daniel A. Pollyea, Dale Bixby, Alexander Perl, Vijaya Raj Bhatt, Jessica K. Altman, Frederick R. Appelbaum, Marcos de Lima, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Meagan Jacoby, Jeffrey Lancet, Gabriel Mannis, Guido Marcucci, Michael G. Martin, Alice Mims, Jadee Neff, Reza Nejati, Rebecca Olin, Mary-Elizabeth Percival, Thomas Prebet, Amanda Przespolewski, Dinesh Rao, Farhad Ravandi-Kashani, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Kendra Sweet, Pankit Vachhani, Matthew Wieduwilt, Kristina M. Gregory, Ndiya Ogba, and Martin S. Tallman

be able to: Integrate into professional practice the updates to the NCCN Guidelines for Acute Myeloid Leukemia Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Acute Myeloid Leukemia Disclosure of

Full access

Therapeutic Advances in First-Line Management of Acute Myeloid Leukemia

Daniel A. Pollyea

Introduction From the 1970s until 2017, there was little progress in the frontline treatment of acute myeloid leukemia (AML). Now, according to Daniel A. Pollyea, MD, MS, Associate Professor, University of Colorado School of Medicine, recent drug

Full access

Novel and Emerging Treatment Strategies for Acute Myeloid Leukemia

Presented by: Eunice S. Wang

Despite the advent of novel targeted therapies and promising emerging strategies, acute myeloid leukemia (AML) remains difficult and challenging to treat. With a median age at diagnosis of 68 years, the incidence of AML is increasing as the general